MARKET

OTIC

OTIC

Otonomy Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.940
+0.070
+3.74%
Closed 16:00 05/19 EDT
OPEN
1.860
PREV CLOSE
1.870
HIGH
1.950
LOW
1.860
VOLUME
74.80K
TURNOVER
87.52K
52 WEEK HIGH
2.590
52 WEEK LOW
1.140
MARKET CAP
110.43M
P/E (TTM)
-2.4856
1D
5D
1M
3M
1Y
5Y
Otonomy to Participate in the H.C. Wainwright Global Investment Conference
SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its participation in the H.C. Wainwright Global Investment Confer...
GlobeNewswire · 1d ago
Otonomy Announces OTO-825 Presentation at the American Society of Gene & Cell Therapy Annual Meeting
SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the presentation of preclinical data for OTO-825 at the upcoming ...
GlobeNewswire · 05/12 11:30
Otonomy GAAP EPS of -$0.20
Otonomy press release (NASDAQ:OTIC): Q1 GAAP EPS of -$0.20. Cash, cash equivalents, and short-term investments totaled $62.9 million as of March 31, 2022, compared to $77.4 million as of December
Seekingalpha · 05/09 20:34
-- Earnings Flash (OTIC) OTONOMY Reports Q1 Loss $-0.20, vs. Street Est of $-0.20
MT Newswires · 05/09 16:28
Earnings Scheduled For May 9, 2022
  Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million.
Benzinga · 05/09 08:52
Notable earnings after Monday's close
ADES, AGM, AIV, AKBA, ALCO, ALTO, AMC, AMPH, AMWL, ANGI, APPF, APTO, ARCT, AROC, ASLE, ASRT, ATER, AVIR, AZTA, BATL, BHF, BLFS, BLI, BLNK, BODY, OTCPK:BOWFF, BRMK, BRT, BW, BWXT,
Seekingalpha · 05/08 21:35
Otonomy Q1 2022 Earnings Preview
Otonomy (NASDAQ:OTIC) is scheduled to announce Q1 earnings results on Monday, May 9th, after market close. The consensus EPS Estimate is -$0.20
Seekingalpha · 05/08 21:35
Earnings Outlook For Otonomy
Otonomy (NASDAQ:OTIC) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that Otonomy will report an earnings per share (EPS) of $-0.20.
Benzinga · 05/06 17:09
More
No Data
Learn about the latest financial forecast of OTIC. Analyze the recent business situations of Otonomy Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

20.00%Strong Buy
80.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average OTIC stock price target is 6.50 with a high estimate of 9.00 and a low estimate of 5.50.
High9.00
Average6.50
Low5.50
Current 1.940
EPS
Actual
Estimate
-0.16-0.12-0.08-0.04
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 59
Institutional Holdings: 36.17M
% Owned: 63.55%
Shares Outstanding: 56.92M
TypeInstitutionsShares
Increased
9
4.73M
New
5
82.44K
Decreased
12
2.10M
Sold Out
16
1.38M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.00%
Pharmaceuticals & Medical Research
+0.51%
Key Executives
Non-Executive Chairman/Independent Director
Jay Lichter
President/Chief Executive Officer/Director
David Weber
Chief Financial Officer
Paul Cayer
Chief Technology Officer
Robert Savel
Chief Scientific Officer
Alan Foster
Director
Jill Broadfoot
Independent Director
James Breitmeyer
Independent Director
Vickie Capps
Independent Director
Ciara Kennedy
Independent Director
Iain McGill
Independent Director
Theodore Schroeder
No Data
No Data
About OTIC
Otonomy, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutics for neurotology. The Company pipeline includes OTIPRIO, OTIVIDEX, OTO-313, and OTO-413. OTIPRIO is a single-dose, physician-administered antibacterial for the treatment of pediatric patients with bilateral otitis media with effusion undergoing TTP surgery for the treatment of patients with acute otitis externa (AOE). OTIVIDEX is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Menieres disease. OTO-313 is a sustained-exposure formulation of gacyclidine, a potent and selective N-Methyl-D-Aspartate (NMDA) receptor antagonist, in development for the treatment of tinnitus. OTO-413 is a sustained-exposure formulation of brain-derived neurotrophic factor (BDNF) in development for the repair of cochlear synaptopathy, an underlying pathology in age-related and noise-induced hearing loss.

Webull offers kinds of Otonomy Inc stock information, including NASDAQ:OTIC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OTIC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OTIC stock methods without spending real money on the virtual paper trading platform.